For the first quarter of this year, Merck KGaA reports adjusted EPS down 12.7% to 2.06 euros and adjusted EBITDA of 1.5 billion euros, down 5.2% organically, on revenues of 5.1 billion, down 1.2% organically.

The German group claims a strong performance in healthcare and solid organic growth in electronics thanks to increased demand for semiconductor materials, while life sciences declined on an unfavorable basis of comparison.

Merck KGaA confirms its qualitative forecasts for 2024, with a return to organic growth. It forecasts revenues of €20.6 to €22.1 billion, adjusted EBITDA of €5.7 to €6.3 billion, and adjusted EPS of €8.05 to €9.10.

Copyright (c) 2024 CercleFinance.com. All rights reserved.